Department of Pathology and Biostatistics, University of Pittsburgh School of Medicine, Pittsburgh, PA 15261, USA
Cancer Gene Ther. 2010 Oct;17(10):694-9. doi: 10.1038/cgt.2010.25. Epub 2010 Jun 11.
Minichromosome complex maintenance component 7 (MCM7) is a critical component of DNA replication licensing. Amplification and overexpression of MCM7 leads to high rate of prostate cancer metastasis. Recent studies indicate that MCM7 genome encodes a putative 'super-oncogene' cluster including MCM7 oncogene and a miRNA cluster that knocks down the expression of several critical tumor-suppressor genes. In this study, we constructed a vector that constitutively expresses small interference RNA (siRNA) specific for MCM7. Introduction of this vector into prostate cancer cell lines PC3 or Du145 decreases the expression of MCM7 by 80%. The vector inhibits DNA synthesis and generates growth arrest of these cancer cells. Severe combined immunodeficient mice were xenografted PC3 or Du145 tumors, and subsequently treated with this vector through tail vein injection with polyethylenimine. The animals had dramatically smaller tumor volume, less metastasis and better survival rate in comparison with the controls. As a result, intervention of MCM7 expression using siRNA approach may hold the promise for treating androgen refractory prostate cancer.
微小染色体维持复合物 7(MCM7)是 DNA 复制许可的关键组成部分。MCM7 的扩增和过表达导致前列腺癌转移率高。最近的研究表明,MCM7 基因组编码了一个假定的“超级癌基因”簇,包括 MCM7 癌基因和一个 miRNA 簇,该簇可下调几个关键肿瘤抑制基因的表达。在这项研究中,我们构建了一个稳定表达针对 MCM7 的小干扰 RNA(siRNA)的载体。将该载体引入前列腺癌细胞系 PC3 或 Du145 中,可使 MCM7 的表达降低 80%。该载体抑制 DNA 合成并导致这些癌细胞的生长停滞。严重联合免疫缺陷小鼠被异种移植 PC3 或 Du145 肿瘤,随后通过尾静脉注射聚乙烯亚胺用该载体进行治疗。与对照组相比,动物的肿瘤体积明显更小,转移更少,存活率更高。因此,使用 siRNA 方法干预 MCM7 表达可能有望治疗雄激素难治性前列腺癌。